Last edition
News about "obesity treatment "
Ascletis Submits 2 IND Applications to the US FDA for the Treatment of Obesity
Ascletis has submitted two IND applications to the US FDA for once-monthly obesity therapies, including ASC36_35, a first-in-class triple-target candidate acting on amylin receptor, GLP-1R and GIPR.
Obesity Treatment | 06/07/2026 | By Akanki
Wegovy Pill Prescriptions Surpass 3 Million as Novo Nordisk Presents New ADA 2026 Data
Novo Nordisk announced that Wegovy pill prescriptions have surpassed 3 million since launch, marking one of the largest US pharmaceutical launches by volume. Most prescriptions are from people new to GLP-1 therapy, expanding access to obesity treatment, while new clinical analyses are being presented at ADA 2026.
Obesity Treatment | 10/06/2026 | By News Bureau | 189
Pfizer's Berobenatide Shows Strong Phase 2b Results with Monthly Dosing
Pfizer’s GLP-1 receptor agonist berobenatide demonstrated robust efficacy and favorable tolerability in a Phase 2b trial, supporting once-monthly dosing.
Obesity Treatment | 08/06/2026 | By News Bureau
Novo Nordisk Launches Wegovy Weight-Loss Pill in UAE, First Market Outside the US
UAE becomes first country outside the United States to offer the oral semaglutide treatment for obesity, marking a key step in Novo Nordisk’s global expansion plans.
Obesity Treatment | 04/06/2026 | By News Bureau
Harbour BioMed Reports Promising Preclinical Data for AI-Driven Drug Candidate LET003
Harbour BioMed announced promising preclinical data for LET003, its first Artificial Intelligence (AI)-enabled drug candidate, highlighting potential as a next-generation obesity therapy targeting ACVR2A/2B.
Obesity Treatment | 18/05/2026 | By News Bureau | 312
Eli Lilly's Foundayo and Lower-Dose Zepbound Maintain Weight Loss in Late-Phase Trials
Eli Lilly and Company reports late-stage trial data showing Foundayo and lower-dose Zepbound helped patients maintain significant long-term weight loss after switching from higher-dose incretin therapies.
Obesity Treatment | 13/05/2026 | By News Bureau | 123
Neuland Laboratories partnership with LIR Life Sciences Corp will focus on developing and manufacturing cell-penetrating peptides to support LIR Life’s patch-based GLP-1/GIP obesity treatment platform.
Obesity Treatment | 07/05/2026 | By News Bureau | 168
Neurocrine Initiates First-in-Human Trial for Novel Obesity Therapy NBIP-2118
Neurocrine launches phase I trial of NBIP-2118, a novel CRF2 agonist aimed at delivering fat-specific weight loss while preserving muscle in obesity treatment.
Obesity Treatment | 05/05/2026 | By News Bureau | 179
UK MHRA Approves Single-Dose 7.2mg Wegovy Injection for Obesity Treatment
The UK Medicines and Healthcare products Regulatory Agency has approved a single-dose 7.2mg Wegovy pen, simplifying weekly treatment for adults with obesity and a BMI of 30 or higher.
Obesity Treatment | 15/04/2026 | By News Bureau | 165
Hoth Therapeutics Reports Positive HT-VA CRADA Data
Hoth Therapeutics reports positive HT-VA data showing GDNF improves liver fat metabolism, reduces fat production and may outperform semaglutide in MAFLD and obesity.
Obesity Treatment | 14/04/2026 | By News Bureau | 190
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy